ArticleFunctional & integrative genomics2026
Hypoxia-driven transcriptional activation of MIR100HG by HIF-1α contributes to adaptive gene regulation in hepatocellular carcinoma.
Article in Functional & integrative genomics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundHepatocellular carcinoma (HCC) develops in a chronically hypoxic microenvironment; however, the contribution of hypoxia-regulated long non-coding RNAs (lncRNAs) remains poorly defined.
aimWe aimed to identify MIR100HG as a hypoxia-responsive regulator in hepatocellular carcinoma (HCC) and to define its transcriptional control by hypoxia-inducible factor 1 alpha.
methodsBasal MIR100HG expression was analyzed in four hepatocellular carcinoma cell lines (Hep3B, Huh-7, SNU-398, and SNU-475) and non-tumorigenic Clone-9 hepatocytes. Hypoxia was induced by cobalt (II) chloride. Proliferation, migration, and clonogenicity were evaluated using functional assays. Promoter analysis, electrophoretic mobility shift assay, chromatin immunoprecipitation quantitative polymerase chain reaction, and 5'-deletion luciferase assays were used to map the hypoxia response elements. Transcriptomic profiling was performed using RNA sequencing, followed by gene set enrichment analysis. Gain- and loss-of-function experiments validated the downstream effects.
resultsMIR100HG expression was highest in Hep3B cells and was significantly induced under hypoxia in all hepatic models, indicating a conserved, oxygen-sensitive response. Hypoxia suppressed proliferation, migration, and clonogenicity, with the strongest inhibition observed in non-tumorigenic hepatocytes under hypoxic conditions. Functional hypoxia response elements were identified within the - 815/+231 promoter region, demonstrating direct transcriptional activation by hypoxia-inducible factor 1 alpha. Transcriptomic analyses revealed the enrichment of hypoxia signaling, oxidative stress, proteasome activity, RNA metabolism, autophagy, and ferroptosis pathways. While hypoxia induced broad transcriptional reprogramming, MIR100HG modulated the expression of selected hypoxia-responsive genes, including the PAGE1 and CTAG2, as demonstrated under hypoxic conditions by RNA-seq and functional perturbation experiments.
conclusionsMIR100HG is a hypoxia-inducible factor 1 alpha-driven long non-coding RNA associated with hypoxia-responsive transcriptional programs in hepatocellular carcinoma and represents a potential biomarker and therapeutic target.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.